CTD among the enrolled patients (61%), followed by MCTD (16%). Hemodynamic characteristics and findings after exercise echocardiography in patients having normal mean PAP, borderline mean PAP, and PH were compared. We also determined the validity of therapeutic intervention.

Results: The values of tricuspid regurgitation pressure gradient (TRPG) were comparable between patients with borderline (31.1 ± 7.8 mmHg) and normal mean PAP (28.3 ± 6.9 mmHg) ($P=0.1572$) but its value became significantly higher in patients with borderline mean PAP (39.1 ± 8.0 mmHg) than in those with normal mean PAP (32.8 ± 7.4 mmHg) after exercise echocardiography ($P=0.0391$). Pulmonary arterial wedge pressure was significantly elevated in patients with borderline mean PAP (12 ± 3 mmHg) compared with that in normal mean PAP (7 ± 3 mmHg) ($P<0.0001$) and its value was comparable to those with overt PH, suggesting the heterogeneity on the cause of borderline mean PAP among CTD patients. The clinical course of 10 patients with borderline mean PAP was studied. Five were treated for precapillary disease, 3 for postcapillary disease, and 2 for interstitial lung disease (ILD). Normalization of mean PAP was seen in 3/4 and 3/3 of the patients treated for precapillary and postcapillary disease, respectively. Deterioration of TRPG was seen in one patient after receiving pulmonary vasodilators. One with severe ILD developed PH.

Conclusions: The pathogenesis of borderline mean PAP, clearly distinctive from normal mean PAP, was heterogeneous as that of manifest PH in CTD patients. Though the clinical course may be altered with appropriate therapeutic intervention, repeated assessment is needed.

References:

- [1] Kovacs G, Olschewski H. Borderline pulmonary pressures in scleroderma - "a pre-pulmonary arterial hypertension" condition? *Arthritis Res Ther* 2015; 17: 123, 015–0649–7.
- [2] Kovacs G, Avian A, Tscherner M, et al. Characterization of patients with borderline pulmonary arterial pressure. *Chest* 2014; 146: 1486–93.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3592

SAT0370 EVALUATIONS OF EXERTION DYSPNEA IN PATIENTS WITH CONNECTIVE TISSUE DISEASE (CTD) BY CPET (CARDIOPULMONARY EXERCISE TESTING) FOR EARLY DETECTING ASSOCIATED PULMONARY HYPERTENSION (APAH)

Y. Nobuhara, Y. Kamei, Y. Fujikawa, T. Nakazawa. *Rheumatology, Osaka saiseikai nakatsu hospital, Osaka, Japan*

Background: Patients with CTD often complain of exertion dyspnea, due to lung diseases, heart diseases, musculoskeletal disorders and/or APAH. Although imaging and physiological tests could reveal pathophysiology, some of them remain unknown. Especially APAH is rarely diagnosed in WHO functional class I or II, because pulmonary vasculopathy (PV) cannot be detected until two-thirds of pulmonary blood vessels deteriorated, ¹ with cardiac ultrasonography (UCG) or right heart catheterization (RHC) at rest. Pathophysiological considerations suggest that the haemodynamic/metabolic impairment in APAH may be observed during exercise before the disease becomes evident at rest.²⁻³ We evaluated exertion dyspnea of unknown to find out early APAH with CPET.

Objectives: We performed CPET in patients who complained of exertion dyspnea and tried to detect early PV.

Methods: From June 13th in 2015 to October 28th in 2016, we performed CPET and evaluate their clinical state in 28 patients, 17–80 years 2 males/26 females, 5 mixed connective tissue disease (MCTD), 15 SSc, 3 SLE, 2 Sjögren's syndrome, 3 dermatomyositis. They underwent UCG, pulmonary function testing (PFT), 6-minutes walk test, and nailfold capillaroscopy by Cutolo's method.⁴

Results: Twenty cases presented decreased peak VO₂. VE/VCO₂ ratio, which represent increased ventilation-perfusion mismatch, elevated in 12 cases. 8 cases, with decreased peak VO₂ but normal VE/VCO₂, were regarded that muscle weakness mainly induced exertion dyspnea, and advised exercise. Twelve cases with decreased peak VO₂ and elevated VE/VCO₂ were estimated to have APAH or/and interstitial lung disease (ILD). Seven of them underwent RHC and 1 case diagnosed as definite APAH, and another 1 case as post capillary PH.

A 34 years MCTD woman without ILD showed an active capillaroscopic pattern, her peak VO₂ decreased (13.9 ml/kg/min.) and nadir VE/VCO₂ elevated (39). Although her mean PAP was normal, we suspected she had early PV and administered PDE5 inhibitor to her and her dyspnea had gone soon and CPET parameters improved.

CPET was also useful for early detections of therapeutic gains in APAH. A SSc woman, diagnosed as APAH by RHC, was performed CPET only 9 days after administration of PDE5 inhibitor. Her peak VO₂ elevated (13.3 to 15.4 ml/kg/min.) and nadir VE/VCO₂ decreased (43.4 to 38.9) promptly.

Thirteen patients showed an early capillaroscopic pattern, 7 an active pattern and 3 a late pattern. Median values of minimum VE/VCO₂ ratio significantly differed ($p<0.05$) in the three capillaroscopic groups, being progressively worse from early to late capillaroscopic pattern.

Conclusions: We performed CPET in every patient safely. Although more research is required, CPET may provide valuable information notably in APAH patients.

References:

- [1] Hachulla E, et al. French PAH-SSc Network. PAH with SSc in patients with

functional class? dyspnea; mild symptoms but severe outcome. *Rheumatology* 2010;49:940–4.

- [2] Grünig E, et al. Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011. *Int J Cardiol* 2011;154:53.
- [3] Domitrescu C, et al. Developing PV in SSc, detected with non-invasive CPET. *PLoS ONE* 2010;5:e14293.
- [4] Cutolo M, et al. Nailfold videocapillaroscopy assessment of microvascular damage in SSc. *J Rheumatol*. 2000 Jan;27(1):155–60.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4184

SAT0371 BONE FRACTURE RISK ASSESSMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES: RESEMBLANCES TO RHEUMATOID ARTHRITIS

Z. Griger, A. Vincze, K. Szabó, J. Gaál, K. Dankó. *Division of Clinical Immunology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary*

Background: Idiopathic inflammatory myopathies are chronic, heterogeneous systemic autoimmune diseases with symmetrical proximal muscle weakness. During the disease course, osteoporosis and bone fractures are more common compared to the healthy population, which can be explained by the chronic inflammation, immobilization, spontaneous falls and steroid treatment, and affect crucially the patients' quality of life. Recently, a WHO fracture risk calculation tool, FRAX score is available, to measure the 10-year probability of osteoporotic fractures. It takes into account relevant clinical risk factors, such as rheumatoid arthritis, however myositis does not exist among the risk factors.

Objectives: Estimation the effect of myositis and myositis related bone mineral densities on bone fracture risk calculated by FRAX tool.

Methods: FRAX score was determined in 71 patients with idiopathic inflammatory myopathies and results were compared with the data from 50 age, sex and BMI matched patients with rheumatoid arthritis. Moreover, osteoporosis related biomarkers, disease related fractures and bone mineral densities were determined using DXA examinations. Statistical analysis was performed with IBM SPSS 20.0 software.

Results: There were no significant differences between the demographical data, biomarkers (Ca, Vitamin D, parathormone level) of the two groups. Disease duration and cumulative steroid dose were higher in the myositis group. Results of the FRAX score without BMD were significantly lower in the patients with myositis, in both fracture risk: major osteoporotic ($8.61 \pm 6.36\%$, vs. $15.59 \pm 12.66\%$; $p: 0.002$) and femur neck ($2.66 \pm 3.24\%$, vs. $6.34 \pm 9.018\%$; $p: 0.003$). T score results of the DXA examination were not significantly different between the two populations (Lumbar1–4: -0.9 ± 1.43 vs. -0.829 ± 1.38 ; $p: 0.829$; Femoral neck: -1.4 ± 1.08 vs. -1.02 ± 1.08 ; $p: 0.93$), but the presence of osteopenia (60% vs. 39.5%) and osteoporosis (13.5% vs. 7%) were more frequent in the myositis group ($p: 0.045$). Disease related fracture was associated with disease duration in the myositis group and with antibody (RF, ACPA) presence in the RA group. FRAX score with BMD results showed no significant differences between the two populations (Major osteoporotic: 9.44 ± 6.72 vs. 13.25 ± 9.43 ; $p: 0.053$; Hip: 2.77 ± 3.01 vs. 3.57 ± 5.08 ; $p: 0.811$).

Conclusions: As far as we know, this is the first study which examine the fracture risk using FRAX score in patients with idiopathic inflammatory myopathies. According to our data, we can conclude that existence of myositis might indicate similar, independent risk factor in fracture probability, like rheumatoid arthritis. Evaluation of fracture risk should be done with DXA result in patients with IIM, otherwise risk could be underestimated. An exact value of the "myositis related risk" could be determined by a 10-year prospective study.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3784

SAT0372 CLINICAL AND SEROLOGICAL ASSOCIATIONS OF AUTOANTIBODIES TO BICD2 AS A NOVEL MARKER FOR SYSTEMIC SCLEROSIS

M. Mahler¹, C. Bentow¹, J. Milo¹, M. Hudson², H.-D. Zucht³, P. Budde³, D. Wirtz³, J. Schulte-Pelkum³, M. Choi⁴, M. Fritzler⁴. ¹Research and Development, Inova Diagnostics, San Diego, CA., United States; ²Department of Medicine, McGill University, Quebec, Canada; ³Protagen, Dortmund, Germany; ⁴Cumming School of Medicine, University of Calgary, Calgary, Canada

Background: Anti-nuclear antibodies (ANA), which are present in approximately 90% of systemic sclerosis (SSc) patient's sera, play an important role in establishing the diagnosis and predicting prognosis of SSc. Recently, a novel autoantibody has been described in SSc patients targeting Cytoskeleton-Like Bicaudal D Protein Homolog 2 (BICD2).

Objectives: The aim of this study was to assess the prevalence and titers of anti-BICD2 antibodies in SSc and controls and to study the clinical associations of this new antibody.

Methods: A total of 502 samples from SSc patients enrolled in the Canadian Scleroderma Research Group (CSRG) cohort were included in this study. Clinical associations were assessed either as anti-BICD2 antibody positivity

with and without other autoantibodies present using 451 SSc patients with complete dataset. Autoantibodies to several scleroderma-related autoantibodies were detected using commercial or research use only kits (Inova Diagnostics, San Diego, USA). P-values below 0.05 were considered significant.

Results: The sensitivity and specificity of anti-BICD2 antibodies were determined as 22.1% and 99.0%, respectively. Receiver operating characteristic (ROC) analysis showed an area under the curve of 0.79 (95% CI 0.75–0.84). The likelihood (LR) and odds ratios (OR) were 17.7 (LR+), 0.8 (LR-) and 20.4 (OR). The prevalence of these autoantibodies was equally distributed between limited and diffuse form of SSc (22.8% and 24.0%). When SSc patients without the classification criteria markers anti-Scl-70, anti-Centromere and anti-RNA Pol III (n=184) were compared with controls, similar performance was obtained as seen in the entire cohort. Results are summarized in table 1 below.

Table 1

Performance Characteristic	Entire SSc cohort (n=502)	Anti-Scl-70, anti-Centromere and anti-RNA Pol III negative (n=184)
Sensitivity	22.1%	13.6%
Specificity	99.0%	99.0%
AUC	0.79 (95% CI 0.75–0.84)	0.78 (95% CI 0.72–0.84)
LR+	28.1	15.6
LR-	0.21	0.13
OR	133.1	123.7

Several statistically relevant clinical associations were found for anti-BICD2 as summarized in table 2 below.

Conclusions: Our data confirm the presence of anti-BICD2 antibodies in SSc patients that may help to differentiate SSc from other systemic autoimmune rheumatic diseases and to stratify SSc patients into more defined subforms of the disease.

Disclosure of Interest: M. Mahler Employee of: Inova Diagnostics, C. Bentow Employee of: Inova Diagnostics, J. Milo Employee of: Inova Diagnostics, M. Hudson: None declared, H.-D. Zucht Employee of: Protagen, P. Budde Employee of: Protagen, D. Wirtz Employee of: Protagen, J. Schulte-Pelkum Employee of: Protagen, M. Choi: None declared, M. Fritzler: None declared

DOI: 10.1136/annrheumdis-2017-eular.2751

SAT0373 EVALUATION OF AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE (CRISS) INDEX IN THE FASSCINATE TRIAL

D. Khanna¹, V. Berrocal¹, C. Denton², A. Jaheris³, H. Spotwood⁴, C. Lin³, J. Siegel³, D. Furst⁵. ¹Univ Michigan, Ann Arbor, United States; ²UCL, London, United Kingdom; ³Genentech, San Francisco, United States; ⁴Roche, Welwyn Garden, United Kingdom; ⁵UCLA, Los Angeles, United States

Background: Treatment with tocilizumab (TCZ) in early systemic sclerosis (SSc; FaSScinate trial) resulted in consistent, but not statistically significant, improvements in skin sclerosis (mRSS) at wks 24 and 48¹. The CRISS index has been proposed as a composite index for trials in SSc². CRISS is a 2-step process that assigns a probability of improvement for each subject ranging from 0.0 [no improvement] to 1.0 [marked improvement]. Step 1 assesses clinically meaningful decline in cardio-pulmonary-renal involvement and assigns a probability of 0.0. For remaining subjects, 5 variables are used to calculate probability of improvement. These are: FVC%, mRSS, patient (PT GA) and physician globals (MD GA), and HAQ-DI.

Objectives: To assess the performance of CRISS index in the FaSScinate trial.

Methods: In FaSScinate, pts ≥18 y with active SSc were randomized 1:1 to TCZ or placebo (PLA) for 48 wks. Step 1 CRISS was captured using review of serious adverse event data. Non-parametric Wilcoxon test was used to assess significant differences between the CRISS scores in both arms. Analyses were carried out for subject who had complete data at baseline and 24 weeks and at baseline and 48 weeks.

Results: 87 pts (43 TCZ, 44 PBO) were enrolled. Baseline characteristics were similar between arms. 4 subjects in the PBO group and none in TCZ met the pre-defined definition of worsening in Step 1 and were given a score of 0.0. For remaining subjects, we calculated probability score for each subject. Using CRISS as a continuous measure, the median score was statistically significant and favored TCZ compared to PBO at wks 24 and 48 (p=0.04 and 0.01; Table). Table also presents the individual components of Step 2 where only FVC% was statistically significant favoring TCZ at wk 48.

Abstract SAT0372 – Table 2

Clinical Association	Whole group (N=451)		BICD2 alone (N=29)		Overlapping BICD2 (N=107)		Negative BICD2 (N=315)		BICD2 alone vs Negative		Overlapping vs Negative	
	Mean (sd) or N (%)	NA	Mean (sd) or N (%)		Mean (sd) or N (%)		Mean (sd) or N (%)		P Values		P Values	
Disease duration since the onset of RP, years	15.4 (12.9%)	18	15.6 (13.7%)		17.5 (12.6%)		14.6 (12.9%)		0.728		0.013	
Diffuse cutaneous disease	138.0 (30.7%)	1	9.0 (31.0%)		23.0 (21.5%)		106.0 (33.8%)		0.766		0.018	
Calcinosis	104.0 (23.2%)	2	8.0 (27.6%)		33.0 (31.1%)		63.0 (20.1%)		0.339		0.019	
Inflammatory myositis	43.0 (9.6%)	4	7.0 (24.1%)		4.0 (3.8%)		32.0 (10.3%)		0.003		0.040	
GERD/reflux	285.0 (69.7%)	42	16.0 (59.3%)		79.0 (81.4%)		190.0 (66.7%)		0.437		0.006	
Antibiotics for bacterial growth	47.0 (10.5%)	5	0.0 (0.0%)		8.0 (7.6%)		39.0 (12.5%)		0.043		0.160	
Interstitial lung disease	123.0 (27.8%)	9	13.0 (46.4%)		17.0 (16.5%)		93.0 (29.9%)		0.071		0.008	
FVC% predicted	93.5 (19.5%)	61	96.0 (20.8%)		98.3 (19.7%)		91.7 (19.1%)		0.304		0.004	

Table 1. Comparison of TCZ and PBO using CRISS index and individual variables at 24 and 48 weeks

	TCZ	PBO**	P value
CRISS, median [IQR] at 24 week	0.23 [0.003; 0.95], N=33	0.008 [0.00; 0.10], N=36	0.04*
CRISS, median [IQR] at 48 week	0.31 [0.008; 0.99], N=27	0.001 [0.00; 0.18], N=35	0.01*
MRSS, mean change at 24 week	-4.2, N=33	-2.1, N=34	0.24
MRSS, mean change at 48 week	-5.9, N=27	-3.2, N=31	0.35
FVC% predicted, mean change at 24 week	-0.78, N=33	-4.4, N=34	0.08
FVC% predicted, mean change at 48 week	-1.6, N=27	-5.1, N=31	0.02
PT GA, mean change at 24 week	-0.41, N=33	-0.10, N=34	0.64
PT GA, mean change at 48 week	-0.69, N=27	-0.45, N=31	0.72
MD GA, mean change at 24 week	-0.94, N=33	-0.80, N=34	0.76
MDGA, mean change at 48 week	-1.81, N=27	-0.73, N=31	0.07
HAQ-DI, mean change at 24 week	0.09, N=33	0.06, N=34	0.76
HAQ-DI, mean change at 48 week	0.00, N=27	0.16, N=31	0.10

*Using Wilcoxon test as CRISS data is not normally distributed. **There are 4 subjects in the PBO who met step 1 and were given a score of 0.0.

Conclusions: In this post-hoc analysis, CRISS index was able to discriminate TCZ from PBO, supporting its validity in an independent cohort.

References:

[1] Khanna D. Lancet. 2016.

[2] Khanna D. Arthritis Rheum. 2016.

Disclosure of Interest: D. Khanna Grant/research support from: NIH/NIAMS and NIH/NIAD, BMS, Pfizer, Consultant for: Actelion, Bayer, BMS, Boehringer Ingelheim, Genentech/Roche, Sanofi-aventis, GSK, Corbus, Cytos, EMD Serono, V. Berrocal: None declared, C. Denton Consultant for: Actelion, Bayer, GSK, CSL Behring, Merck-Serono, Genentech-Roche, Inventiva, Sanofi-Aventis, Boehringer Ingelheim, A. Jaheris Shareholder of: Roche stock and options, Employee of: Genentech, H. Spotwood Employee of: Roche, C. Lin Employee of: Genentech, J. Siegel Employee of: Genentech, D. Furst Grant/research support from: Amgen, BMS, NIH, Novartis, Pfizer, Roche/Genentech, Consultant for: AbbVie, Amgen, BMS, Cytos, Novartis, Pfizer, Roche/Genentech, UCB

DOI: 10.1136/annrheumdis-2017-eular.3754

SAT0374 THE EUROMYOSITIS REGISTRY: AN INTERNATIONAL DESCRIPTION OF MYOSITIS

J.B. Lilleker¹, J. Vencovsky², G. Wang³, L.R. Wedderburn⁴, L.P. Diederichsen⁵, J. Schmidt⁶, P. Jordan⁷, O. Benveniste⁸, M.G. Danieli⁹, K. Dankó¹⁰, N.T.P. Thuy¹¹, M. Vazquez-Del Mercado¹², Ø. Molberg¹³, B. De Paeppe¹⁴, J. De Bleecker¹⁵, B. Maurer¹⁶, N. Pipitone¹⁷, N. McHugh^{18,19}, Z. Betteridge^{18,19}, P. New²⁰, R.G. Cooper²⁰, W.E. Ollier¹, J.A. Lamb¹, N.S. Krogh²¹, I.E. Lundberg²², H. Chinoy²³ on behalf of UKMYONET and all contributors to the EuroMyositis Registry. ¹Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom; ²Institute of Rheumatology, Charles University, Prague, Czech Republic; ³Rheumatology, China-Japan Friendship Hospital, Beijing, China; ⁴UCL GOS Institute of Child Health, London, United Kingdom; ⁵Rheumatology, Odense University Hospital, Odense, Denmark; ⁶Neurology, University Medical Center, Göttingen, Germany; ⁷Myositis UK, Southampton, United Kingdom; ⁸Médecine Interne et Immunologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France; ⁹Scienze Cliniche e Molecolari, Università Politecnica delle Marche e Ospedale Riuniti, Ancona, Italy; ¹⁰Immunology, University of Debrecen, Debrecen, Hungary; ¹¹Rheumatology, Bach Mai Hospital, Hanoi, Viet Nam; ¹²Medicina Interna, Hospital Civil Dr. Juan I. Menchaca, Guadalupe, Mexico; ¹³Rheumatology, Oslo University Hospital, Oslo, Norway; ¹⁴Neurology; ¹⁵Ghent University Hospital, Ghent, Belgium; ¹⁶Rheumatology, University Hospital Zurich, Zurich, Switzerland; ¹⁷Rheumatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy; ¹⁸Royal National Hospital for Rheumatic Diseases; ¹⁹Pharmacy and Pharmacology, University of Bath, Bath; ²⁰Rheumatology, Salford Royal NHS Foundation Trust, Salford, United Kingdom; ²¹ZiteLab ApS, Frederiksberg, Denmark; ²²Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; ²³NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom

Background: The idiopathic inflammatory myopathies (IIM) represent a rare and heterogeneous group of multisystem autoimmune diseases. The rarity of IIM has